What Dolospam Treats: Main Uses and Benefits

Dolospam may be part of symptomatic management for acute, severe spastic pain and cramping (colic) in organs such as the urinary, biliary, and gastrointestinal tracts. Its antispasmodic action is relevant for conditions like ureteral and biliary colic. It is often used during phases when symptoms become more noticeable, and contributes to improved comfort during periods of heightened symptoms.

---

The medication is also applied across domains where additional symptomatic support is needed for conditions associated with acute or disruptive episodes of arterial spasm. The medication is considered relevant for easing symptoms associated with ureteral colic, biliary colic, Raynaud's Phenomenon, Intermittent Claudication, and severe gastrointestinal spasm. It is used for managing symptom clusters that may become intense or disruptive, such as pain and cramping related to restricted circulation.

“The medication contributes to easing the overall symptom load and provides supportive relief when symptoms interfere with routine activities.”

Quick Fact: Support for Acute Visceral Pain Symptoms

The injectable form is relevant when supportive symptom management is appropriate, and is commonly used in settings where short-term symptom stabilization is important for managing severe visceral organ spasm and intense peripheral arterial constriction.

Regulatory References

1. NIH DailyMed overview

Official Eligibility and Contraindication Profile

The eligibility for the injectable medicine Dolospam is strictly defined by regulatory authorities based on the established safety profile of its components (Atropine and Papaverine). Use is primarily established for the Adult population.

Absolute Contraindications

Dolospam is formally contraindicated in several patient groups, meaning the medicine must not be used:

• Patients with documented hypersensitivity to Atropine, Papaverine, or any ingredient in the formulation.
• Individuals with pre-existing conditions that are highly sensitive to anticholinergic effects, such as narrow-angle glaucoma (untreated or uncontrolled), obstructive uropathy (like prostatic hypertrophy leading to retention), or obstructive diseases of the gastrointestinal tract (e.g., paralytic ileus).
• Patients with complete atrioventricular (AV) heart block or severe underlying cardiac conduction issues.

Population Restrictions and Cautions

• Pediatric Use: The safety and effectiveness in children have not been established by regulatory bodies, and use is generally not recommended in this population.
• Pregnancy and Lactation: Use during pregnancy (often classified as Category C) and breastfeeding is not recommended unless necessary, due to a lack of adequate human data and the known excretion of one component into breast milk.
• Conditional Use: The drug should be used with caution in older adults, patients with severe hepatic or renal impairment, and those with unstable cardiovascular disease, reflecting an increased risk of specific adverse effects in these groups.

The interaction profile of Dolospam is defined by documented restrictions and additive effects derived from its two active components, Atropine and Papaverine.

Contraindicated Combinations and Avoidance Rules

The most restrictive classification is the formal contraindication for intravenous administration when complete atrioventricular (AV) heart block is present, as the Papaverine component may depress cardiac conduction. Specific co-administration rules are also noted for Levodopa: use of the drug should be avoided in patients with Parkinson's disease due to the documented risk of interference with Levodopa's therapeutic effect, potentially worsening symptoms.

Documented Pharmacodynamic and Pharmacokinetic Interactions

Several agents exhibit pharmacodynamic interactions leading to potentiation. Co-administration with CNS depressants, including Barbiturates and Benzodiazepines, is associated with an additive effect that results in enhanced central nervous system depression. Morphine also shows documented synergism with Papaverine. Furthermore, official labeling notes that Pralidoxime may potentiate Atropine's effects, causing signs of atropinization to appear earlier.

A pharmacokinetic interaction is documented where the Atropine component decreases the rate of absorption of the antiarrhythmic agent Mexiletine.

Procedural Interaction Constraints

A procedural constraint exists: Papaverine is chemically incompatible with Lactated Ringer's Injection and must not be mixed with this solution due to the formation of a precipitate.

How Dolospam Works: Mechanism of Action

Dolospam employs a dual-pathway approach to modulate involuntary muscle activity by combining a signal blocker and a direct muscle relaxant. This approach facilitates smooth muscle relaxation by addressing both the neurogenic component and the myogenic component of contraction.

---

Interrupting Neurogenic Spasm Signals

This domain addresses the action of Atropine, which acts as a competitive antagonist at the muscarinic acetylcholine receptors ( M3) located on smooth muscle cells. By blocking the binding of the neurotransmitter Acetylcholine (ACh), the drug suppresses the nerve-driven signal that initiates the involuntary contraction. This interference with the parasympathetic pathway limits excessive signaling, resulting in a reduction of involuntary smooth muscle tone.

---

Direct Modulation of Intracellular Muscle Tension

This domain covers the action of Papaverine, which is a non-selective inhibitor of Phosphodiesterase (PDE) enzymes within the smooth muscle cell. PDE inhibition leads to increased intracellular levels of the relaxing messengers, cyclic AMP (cAMP) and cyclic GMP (cGMP). This molecular cascade results in a reduction in the concentration of calcium ions ( Ca^2+) available for contraction, which is the mechanism of non-neurogenic, myogenic tone reduction and vasodilation.

How to Use Dolospam: Official Administration Guidelines

Dolospam (Atropine/Papaverine Injectable Solution) is a medication intended for acute, short-term symptomatic use and is administered solely via the parenteral route in a clinical setting. Its usage protocol is strictly defined according to the established protocols for its constituent components, which dictates the procedural aspects of administration.

---

Administration Scope and Requirements

Instruction Entity	Official Administration Guideline
Route of Administration	The official approved routes are Intravenous (IV) Injection and Intramuscular (IM) Injection.
Dosing Schedule	The regimen is structured for intermittent, as-needed (PRN) use, reserved for acute episodes of spasm. It is not intended for continuous daily maintenance therapy.
Preparation Requirements	The sterile liquid solution must be visually inspected for any particles or discoloration prior to administration. The Papaverine component should not be mixed with Lactated Ringer's Injection due to potential incompatibility issues.
Administration Speed	For the IV route, the injection must be performed slowly, typically over a period of 1 to 2 minutes for the Papaverine component, which is a critical procedural condition.

---

Procedural and Population Constraints

The usage protocol is based on the requirement that the medication must be administered by a professional in a monitored clinical environment. Administration guidelines require specific considerations for patient age groups: use is generally not established or restricted in pediatric patients, and caution is advised for use in older adults. Because the drug is used only to manage acute episodes, it does not have scheduled missed-dose rules, and its duration of use is limited to the short-term management of the immediate acute event.

Research Evidence / Overview of Studies for Dolospam

The information below describes the research structure and what studies have evaluated. Research provides context but does not determine individual outcomes.

Evidence for Use in Acute Visceral Colic

Research relevant to this combination was studied for conditions characterized by episodic manifestations, such as colic associated with the urinary or biliary tracts.

The available evidence comes from short-term Randomized Controlled Trials (RCTs) and comparative prospective studies. These were used in research exploring how symptoms change over time and to measure patient-reported outcomes describing perceived discomfort. A key measure was the assessment of symptom intensity or variability and the requirement for rescue analgesia (additional pain medication).

Studies evaluating the Papaverine component often alongside other treatments like NSAIDs, explored short-term symptom changes in the observed populations. These findings describe patterns observed in the studies over the immediate, very short-term period, generally within the first hour after administration. Research describes patterns related to the need for supplemental pain relief in some cohorts.

However, the majority of this evidence comes from research examining the individual component rather than the specific, fixed-dose combination with Atropine. Comparative evidence is lacking regarding the fixed-dose combination itself for this acute indication.

Research on Acute Arterial Spasm and Localized Vasodilation

The Papaverine component was studied for conditions associated with localized arterial spasm. The research foundation includes controlled clinical trials and specialized pharmacological studies conducted during periods of increased symptom activity in controlled procedural environments.

Trials on the Papaverine component reported measurements of localized vasodilation and subsequent changes measured in blood flow in acute procedural settings. The research describes patterns where the spasmolytic agent was associated with outcomes related to physiological strain in the vessel wall. These findings provide insight into short-term changes.

Limitations of Evidence and Component-Based Findings

Certainty remains low regarding the comprehensive profile of the fixed-dose combination, largely due to the reliance on individual component data and the short follow-up durations. The data show patterns related to the Papaverine component's research being highly specific to acute procedures. Few data are available for specialized populations, such as children, pregnant individuals, or older adults with multiple co-existing medical conditions.

Key Studies & References

1. NIH DailyMed Drug Information: Official Monograph for combination Antispasmodic Product
2. Antispasmodic agents for acute abdominal pain in the emergency setting: A systematic review

Common questions about Dolospam (FAQ)

Q: What is Dolospam used for?

Dolospam is a medication used for the symptomatic treatment of spasms (sudden, painful contractions) of the digestive tract, such as intestinal spasms, as well as biliary (gallbladder/bile duct) and renal (kidney) colic. It is also used to help relieve pain associated with menstrual cramps (dysmenorrhea).

---

Q: How does Dolospam work?

Dolospam is a combination of two active ingredients that work together to relax involuntary muscles and decrease spasm activity:

• Atropine sulfate is an antispasmodic agent that helps relax the smooth muscles in the walls of the gastrointestinal and genitourinary tracts.
• Papaverine hydrochloride is also an antispasmodic and vasodilator that directly relaxes smooth muscles, particularly in the bowel and in blood vessels.

---

Q: Should I take Dolospam with food?

Dolospam tablets should be administered with water.

---

Q: What are the common side effects of Dolospam?

As with most medications, Dolospam may cause side effects. Due to the presence of atropine, some effects are more common, especially at normal doses. These can include:

• Vision changes (such as blurred vision and dilated pupils)
• Dryness of the nose and mouth
• Constipation and abdominal distension
• Retention of urine
• Flushing or reddening of the face (bochorno)
• Slow heart rate (bradycardia)

If you experience eye pain, you should stop taking the medication immediately and consult your doctor.

---

Q: Can I take Dolospam if I am pregnant or breastfeeding?

Dolospam should be avoided during pregnancy and breastfeeding. The safety of this medicine during these periods has not been fully established. It is important to consult your healthcare provider before taking this medication if you are pregnant, planning to become pregnant, or breastfeeding.

---

Q: What should I tell my doctor before taking Dolospam?

It is important to inform your doctor if you have certain existing health conditions, as Dolospam should be used with caution or is contraindicated in some cases. You should tell your doctor if you have:

• Glaucoma (elevated eye pressure)
• Paralytic ileus or pyloric stenosis (conditions of the bowel that cause obstruction)
• Myasthenia gravis (a neuromuscular disease)
• Urinary retention
• Ulcerative colitis
• Reduced gastrointestinal movement (motility)
• An enlarged prostate (prostatic hypertrophy)
• Unstable cardiovascular disease or conduction disorders of the heart
• High blood pressure (hypertension)
• Are over the age of 65 (senescentes)

How to Store and Dispose of Dolospam?

The injectable solution of Dolospam (Atropine/Papaverine) must be stored strictly according to regulatory labeling to maintain its stability and sterility.

---

Storage Requirements

• Temperature and Protection: The product must be stored at Controlled Room Temperature (typically 20 C to 25 C) and must Not Freeze. The ampoules must be protected from light and kept in the original carton until use.
• Child Safety: Store the product out of the sight and reach of children.
• Single-Use Rule: As a single-dose preparation, the ampoule is for single use only; any unused solution remaining after administration must be discarded immediately.

---

Disposal Instructions

Disposal of unused or expired Dolospam, including the container, must be conducted in accordance with local/regional regulations. The product should not be allowed to enter sewers, water courses, or wastewater, and should be returned to a pharmacist for proper pharmaceutical waste handling.